To the full analysis
Recordati Industria Chimica e Farmaceutica stock: growth
REC.MIRecordati Industria Chimica e Farmaceutica reported $2.9B in revenue for fiscal 2025, up 11.8% on the prior year, up 12.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
8.3%
per year from 2006 to 2025, per share 8.1%
Earnings (Annual rate)
9.9%
per year from 2006 to 2025, per share 9.7%
Free cash flow (Annual rate)
10.6%
per year from 2006 to 2025, per share 10.4%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 12.6% | 9.6% | 8.3% |
| Revenue per share | 12.6% | 9.6% | 8.1% |
| Earnings | 4.6% | 8.4% | 9.9% |
| Earnings per share | 4.5% | 8.3% | 9.7% |
| Free cash flow | 13.5% | 9.1% | 10.6% |
| Free cash flow per share | 13.5% | 9.1% | 10.4% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $638.47M | $82.03M | $84.24M |
| 2007 | $696.37M | $94.04M | $85.14M |
| 2008 | $764.18M | $111.29M | $115.14M |
| 2009 | $828.33M | $122.52M | $140.31M |
| 2010 | $806.85M | $120.32M | $117.46M |
| 2011 | $844.41M | $129.03M | $85.59M |
| 2012 | $917.86M | $131.29M | $55.28M |
| 2013 | $1.04B | $148.13M | $101.97M |
| 2014 | $1.09B | $178.61M | $170.7M |
| 2015 | $1.16B | $220.28M | $236.78M |
| 2016 | $1.28B | $263.07M | $242.11M |
| 2017 | $1.43B | $319.98M | −$53.18M |
| 2018 | $1.5B | $346.14M | $318.05M |
| 2019 | $1.64B | $408.69M | −$137.87M |
| 2020 | $1.61B | $393.36M | $301.29M |
| 2021 | $1.75B | $427.69M | $447.99M |
| 2022 | $2.05B | $346.1M | $404.85M |
| 2023 | $2.31B | $431.29M | $113.09M |
| 2024 | $2.59B | $461.53M | $592.94M |
| 2025 | $2.9B | $491.58M | $567.1M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Sep 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.